| Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. |
Recruiting |
Maximum Tolerated Dose|GIST|Metastatic Adult Soft Tissue Sarcoma|Drug Toxicity|Drug Use |
NCT04138381 |
| Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas |
Terminated |
Plexiform Neurofibromas |
NCT02177825 |
| Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log |
Unknown status |
Leukemia, Myeloid, Chronic-Phase |
NCT03239886 |
| A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. |
Recruiting |
Papillary Thyroid Cancer |
NCT03469011 |
| Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator |
Active, not recruiting |
GIST and CML |
NCT01742299 |
| Imatinib in Acute Ischaemic Stroke |
Recruiting |
Acute Ischaemic Stroke |
NCT03639922 |
| Population Pharmacokinetics of Imatinib in CML Patients in Iran |
Terminated |
Chronic Myelogenous Leukemia |
NCT02146846 |
| Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response |
Active, not recruiting |
Leukemia, Chronic Myeloid |
NCT02852486 |
| Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma |
Unknown status |
Mesothelioma, Malignant |
NCT02303899 |
| Entacapone Combination With Imatinib for Treatment of GIST |
Not yet recruiting |
Gastrointestinal Stromal Tumor, Malignant |
NCT04006769 |
| Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST |
Recruiting |
Sarcoma |
NCT02413736 |
| Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL |
Active, not recruiting |
ALK+ Anaplastic Large Cell Lymphoma |
NCT02462538 |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) |
Recruiting |
CML|Chronic Myelogenous Leukemia|Leukemia, Myeloid Chronic|Hematologic Diseases |
NCT03578367 |
| Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) |
Suspended |
Gastrointestinal Stromal Tumors|Resected Gastrointestinal Stromal Tumors|Non-metastatic|High Risk of Recurrence|KIT Gene Mutation |
NCT02260505 |
| Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria |
Unknown status |
Plasmodium Falciparum Malaria |
NCT02614404 |
| Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy |
Terminated |
Colonic Neoplasms |
NCT02685046 |
| Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) |
Recruiting |
Chronic Myeloid Leukemia, Chronic Phase |
NCT03722420 |
| Imatinib for Multiple Sclerosis (MS) Relapses |
Recruiting |
Multiple Sclerosis |
NCT03674099 |
| Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study |
Not yet recruiting |
Cervical Spinal Cord Injury |
NCT02363361 |
| KISS Study: Kinase Inhibition With Sprycel Start up |
Recruiting |
Chronic Myeloid Leukemia |
NCT03193281 |
| Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) |
Unknown status |
Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+) |
NCT01221376 |
| Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT |
Completed |
Gastrointestinal Stromal Tumors |
NCT01151852 |
| Imatinib in KIT-negative Systemic Mastocytosis |
Completed |
Systemic Mastocytosis |
NCT01297777 |
| Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) |
Suspended |
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) |
NCT01222013 |
| Study of Imatinib in Children With Neurofibromatosis and Airway Tumors |
Recruiting |
Neurofibroma, Plexiform |
NCT03688568 |
| Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa |
Recruiting |
Loaisis |
NCT02644525 |
| Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes |
Completed |
Hypereosinophilic Syndrome|Chronic Eosinophilic Leukemia|Chronic Idiopathic Hypereosinophilia |
NCT00787384 |
| Imatinib for Pain in Sickle Cell Anemia |
Not yet recruiting |
Sickle Cell Disease |
NCT03997903 |
| Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body |
Completed |
Chronic Myeloid Leukemia |
NCT01795716 |
| A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST |
Completed |
Gastrointestinal Stromal Tumor (GIST) |
NCT01294202 |
| Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease |
Completed |
Sclerotic Graft Versus Host Disease|Imatinib Mesylate |
NCT00702689 |
| Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) |
Completed |
Asthma |
NCT01097694 |
| SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST |
Recruiting |
Gastrointestinal Stromal Tumor |
NCT02924714 |
| Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas |
Completed |
Neurofibromatosis|Neurofibromas |
NCT01140360 |
| LAM Pilot Study With Imatinib Mesylate |
Completed |
Lymphangioleiomyomatosis |
NCT03131999 |
| Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy |
Recruiting |
Advanced, Refractory Cancer |
NCT02461849 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia |
Unknown status |
Chronic Myeloid Leukemia |
NCT02317159 |
| A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis) |
Completed |
Fibromatosis |
NCT02495519 |
| Drug-drug Interaction Study With Metformin and Imatinib |
Completed |
Healthy |
NCT01404715 |
| Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance |
Completed |
Leukemia, Myeloid, Chronic, BCR-ABL Positive |
NCT01819389 |
| Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response |
Terminated |
Leukemia, Myeloid, Chronic-Phase |
NCT01827930 |
| A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase |
Completed |
Leukemia |
NCT02272777 |
| Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children |
Active, not recruiting |
Chronic Graft-versus-host Disease |
NCT01898377 |
| Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib |
Unknown status |
Chronic Myeloid Leukemia |
NCT01400074 |
| ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma |
Unknown status |
Lymphoma, Non-Hodgkin |
NCT02431403 |
| Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors |
Withdrawn |
Gastrointestinal Stromal Tumors |
NCT02268435 |
| Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma |
Completed |
Mucosal Melanoma|Acral/Lentiginous Melanoma|Chronically Sun Damaged Melanomas |
NCT00424515 |
| Effect of Pharmacogenetics on Imatinib Plasma Level and Response |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT03262974 |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia |
Completed |
Myeloid Leukemia, Chronic, Chronic Phase |
NCT01460693 |
| A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) |
Completed |
Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumor |
NCT01751919 |
| Imatinib (QTI571) in Pulmonary Arterial Hypertension |
Completed |
Pulmonary Arterial Hypertension |
NCT00902174 |
| Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy |
Completed |
Chronic Myeloid Leukemia |
NCT00858806 |
| Ph II Study of Perifosine Plus Gleevec for Patients With GIST |
Completed |
Gastrointestinal Stromal Tumors |
NCT00455559 |
| Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients |
Completed |
Chronic Myeloid Leukemia |
NCT01578213 |
| Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment |
Not yet recruiting |
Gastrointestinal Stromal Tumors|Surgery |
NCT03862768 |
| Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus |
Completed |
Diabetes Mellitus, Type I|Diabetes Mellitus, Insulin-Dependent, 1|Type 1 Diabetes Mellitus|Insulin-Dependent Diabetes Mellitus 1|IDDM |
NCT01781975 |
| A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury |
Completed |
Acute Lung Injury |
NCT03328117 |
| Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans |
Completed |
Dermatofibrosarcoma Protuberans |
NCT00243191 |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes |
Completed |
Hypereosinophilic Syndrome|Systemic Mastocytosis|Chronic Myelomonocytic Leukemia|Dermatofibrosarcoma |
NCT00171912 |
| Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) |
Completed |
Gastrointestinal Stromal Tumor (GIST) |
NCT00867113 |
| Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy |
Terminated |
Gastrointestinal Stromal Tumor|Major Gastrectomy |
NCT02185937 |
| Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia |
Withdrawn |
Chronic Myeloid Leukemia |
NCT02115672 |
| Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI |
Active, not recruiting |
Gastrointestinal Stromal Tumors |
NCT01541709 |
| Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt |
Active, not recruiting |
Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase |
NCT03454503 |
| Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors |
Completed |
Gastrointestinal Stromal Tumors |
NCT01275222 |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma |
Completed |
Glioblastoma|Gliosarcoma |
NCT00613054 |
| Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma |
Terminated |
Scleroderma |
NCT01545427 |
| Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis |
Completed |
Nephrogenic Systemic Fibrosis |
NCT00677092 |
| PDR001 Plus Imatinib for Metastatic or Unresectable GIST |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT03609424 |
| Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) |
Terminated |
Leukemia, Myeloid, Chronic Phase |
NCT00124748 |
| Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma |
Terminated |
Thyroid Cancer |
NCT00115739 |
| Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia |
Not yet recruiting |
Chronic Myeloid Leukemia |
NCT03228303 |
| Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
Completed |
Neurofibromatosis |
NCT01673009 |
| Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation |
Terminated |
Patients Who Have Received Allo-HSCT |
NCT03343600 |
| A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor |
Recruiting |
Desmoid Tumor |
NCT03802084 |
| Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation |
Completed |
Sarcoma|Gastrointestinal Stromal Tumors |
NCT00278876 |
| Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) |
Terminated |
Pulmonary Arterial Hypertension |
NCT01117987 |
| Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma |
Terminated |
Solid Tumor|Thyroid Cancer |
NCT00354523 |
| A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) |
Withdrawn |
Chronic Myelogenous Leukemia |
NCT01011998 |
| Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma |
Completed |
Glioblastoma|Gliosarcoma |
NCT00354913 |
| Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
Terminated |
GIST|Metastatic Disease |
NCT01089595 |
| BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) |
Completed |
Advanced Gastrointestinal Stromal Tumor (GIST) |
NCT02257541 |
| Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers |
Completed |
Healthy |
NCT01504984 |
| Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT00441155 |
| Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma |
Completed |
Sarcoma |
NCT00090987 |
| A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia |
Completed |
Health Care Quality|Health Care Evaluation |
NCT01227356 |
| A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) |
Completed |
Myelofibrosis|Myeloid Metaplasia|Agnogenic Myeloid Metaplasia|Chronic Myelomonocytic Leukemia |
NCT00136409 |
| Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. |
Terminated |
Chronic Myeloid Leukemia (CML)|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)|Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN) |
NCT01066468 |
| Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor|Metastatic Cancer |
NCT00764595 |
| Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
Terminated |
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia |
NCT01383447 |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
Active, not recruiting |
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive |
NCT02130557 |
| Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase |
Active, not recruiting |
Philadelphia Chromosome Positive CML|BCR-ABL Positive Chronic Myelogenous Leukemia |
NCT04070443 |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy |
Completed |
Prostatic Neoplasm|Genital Neoplasms, Male|Neoplasms, Abdominal|Urogenital Neoplasms|Genital Diseases, Male|Prostatic Diseases|Antineoplastic Agents|Imatinib |
NCT01316458 |
| An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints |
Completed |
CML|Imatinib |
NCT01216085 |
| A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene |
Completed |
Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST) |
NCT00237185 |
| Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cancer |
NCT00928642 |
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) |
Terminated |
Recurrent Glioblastoma Multiforme (GBM) |
NCT00290771 |
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia |
Completed |
Chronic Myeloid Leukemia |
NCT00852566 |
| Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate |
Completed |
Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Polycythemia Vera|Hypereosinophilic Syndrome|Mastocytosis |
NCT00038675 |
| Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00080665 |
| Study to Evaluate Imatinib in Desmoid Tumors |
Completed |
Aggressive Fibromatosis|Desmoid Tumor |
NCT01137916 |
| Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) |
Completed |
Gastrointestinal Stromal Tumors |
NCT01172548 |
| Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia |
Recruiting |
Chronic Myelogenous Leukemia |
NCT01316250 |
| Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia |
Completed |
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia |
NCT00154349 |
| MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) |
Recruiting |
Gastrointestinal Stromal Tumor (GIST) |
NCT01991379 |
| An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years |
Terminated |
Chronic Myeloid Leukemia |
NCT02174445 |
| Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate |
Completed |
Progressive Gastrointestinal Stromal Tumor |
NCT00510354 |
| Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT01083589 |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) |
Completed |
Glioblastoma|Gliosarcoma |
NCT00615927 |
| A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome |
Terminated |
Hypereosinophilic Syndrome |
NCT00171860 |
| Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor |
NCT01267695 |
| A Study of Nilotinib Versus Imatinib in GIST Patients |
Completed |
Gastrointestinal Stromal Tumor (GIST) |
NCT00785785 |
| Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans |
Completed |
Adult Fibrosarcoma|Dermatofibrosarcoma Protuberans|Recurrent Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma |
NCT00084630 |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer |
Completed |
Head and Neck Cancer|Squamous Cell Cancer |
NCT00485485 |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT01011075 |
| Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis |
Completed |
Systemic Sclerosis |
NCT00555581 |
| Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) |
Completed |
Gastrointestinal Stromal Tumors |
NCT00171977 |
| A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis |
Completed |
Alveolitis|Systemic Sclerosis |
NCT00512902 |
| Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00216112 |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) |
Terminated |
Myelogenous Leukemia |
NCT00519090 |
| Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00686218 |
| Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) |
Completed |
Gastrointestinal Stromal Tumors |
NCT00135005 |
| A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis. |
Completed |
Rheumatoid Arthritis |
NCT00154336 |
| Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors |
Completed |
Refractory Malignancy|Solid Tumors |
NCT00611689 |
| Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib |
Recruiting |
Chronic Myeloid Leukaemia |
NCT01475110 |
| Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects |
Completed |
Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumors |
NCT01270984 |
| Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma |
Completed |
Uterine Cancer |
NCT00506779 |
| Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) |
Completed |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT02480608 |
| Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients |
Terminated |
Leukemia |
NCT00499889 |
| Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors |
Completed |
Refractory Desmoplastic Small Round Cell Tumors |
NCT00417807 |
| Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment |
Completed |
Chronic Myeloid Leukemia|Newly Diagnosed |
NCT00632255 |
| Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib |
Terminated |
Leukemia, Myeloid, Chronic |
NCT00320190 |
| Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT02896829 |
| A Global Imatinib and Nilotinib Pregnancy Exposure Registry |
Completed |
All Indications for Glivec/Gleevec and Tasigna |
NCT01289054 |
| Effect of Food on Bioavailability of Modified Release Formulations of Imatinib |
Completed |
Healthy |
NCT00420043 |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib |
Active, not recruiting |
Chronic Phase Chronic Myeloid Leukemia |
NCT01593254 |
| Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients |
Terminated |
Gastrointestinal Stromal Tumors |
NCT01031628 |
| Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients |
Terminated |
Chronic Lymphocytic Leukemia |
NCT00558961 |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma |
Completed |
Glioblastoma Multiforme|Astrocytoma |
NCT00154375 |
| Imatinib in Patients With Desmoid Tumor and Chondrosarcoma |
Unknown status |
Advanced Desmoid Tumor|Advanced Chondrosarcoma |
NCT00928525 |
| A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia |
Withdrawn |
Chronic Myeloid Leukemia, Blast Crisis|Acute Myeloid Leukemia |
NCT00594555 |
| Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia |
Unknown status |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT02687425 |
| Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib |
Completed |
Healthy |
NCT00422825 |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients |
Completed |
Leukemia|Leukemia, Myeloid|Leukemia, Myelogenous, Chronic, BCR-ABL Positive|Philadelphia Chromosome|Bone Marrow Diseases|Hematologic Diseases |
NCT01511289 |
| Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen |
Completed |
Seasonal Allergic Rhinitis |
NCT00426179 |
| A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia |
Completed |
Leukemia |
NCT01126814 |
| Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma |
Completed |
T Cell Non-Hodgkin Lymphoma |
NCT00684411 |
| An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis |
Completed |
Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis |
NCT00171158 |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients |
Completed |
Leukemia |
NCT00386373 |
| Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery |
Completed |
Gastrointestinal Stromal Tumor |
NCT00025246 |
| Ipilimumab and Imatinib Mesylate in Advanced Cancer |
Recruiting |
Advanced Malignant Solid Neoplasm|C-KIT Tyrosine Kinase Protein Overexpression|Clinical Stage IV Cutaneous Melanoma AJCC v8|Metastatic Gastrointestinal Stromal Tumor|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Melanoma|Unresectable Solid Neoplasm |
NCT01738139 |
| A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) |
Completed |
Myelogenous Leukemia, Chronic |
NCT00471497 |
| Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST |
Completed |
Gastrointestinal Stromal Tumors |
NCT00500188 |
| A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients |
Completed |
3rd Line GIST |
NCT01468688 |
| Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension |
Completed |
Pulmonary Arterial Hypertension |
NCT00477269 |
| A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors |
Completed |
Advanced Gastrointestinal Stromal Tumors |
NCT00940563 |
| A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) |
Recruiting |
Gastrointestinal Stromal Tumour |
NCT02365441 |
| Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML |
Completed |
Chronic Myeloid Leukemia |
NCT00574873 |
| Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host |
Completed |
Graft Versus Host Disease |
NCT02891395 |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) |
Completed |
CHRONIC MYELOGENOUS LEUKEMIA |
NCT00760877 |
| Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) |
Completed |
Gastrointestinal Stromal Tumors |
NCT01483014 |
| Study of Temzolomide and Gleevec in Advanced Melanoma |
Terminated |
Melanoma|Advanced Melanoma |
NCT00667953 |
| Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma |
Terminated |
Gastric Adenocarcinoma |
NCT00209079 |
| Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib |
Completed |
Chronic Myelogenous Leukemia |
NCT00802841 |
| Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia |
Terminated |
Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia |
NCT02709083 |
| Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma |
Completed |
Brain and Central Nervous System Tumors |
NCT00387933 |
| A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma |
Unknown status |
Melanoma |
NCT01782508 |
| CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) |
Completed |
Leukemia |
NCT00955916 |
| Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification |
Withdrawn |
Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma |
NCT02812693 |
| Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation |
Completed |
Chronic Myeloid Leukemia |
NCT00219726 |
| A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia |
Unknown status |
Myelogenous Leukemia, Chronic |
NCT01503502 |
| Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease |
Completed |
Graft Versus Host Disease|Systemic Scleroderma |
NCT01309997 |
| Therapy of Early Chronic Phase CML With Gleevec |
Completed |
Leukemia, Myeloid, Chronic-Phase |
NCT00048672 |
| Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) |
Completed |
Sarcoma |
NCT00116935 |
| Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG |
Completed |
Glioblastoma|Gliosarcoma |
NCT00613132 |
| Imatinib in Systemic Sclerosis |
Completed |
Scleroderma, Systemic |
NCT00506831 |
| Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg |
Terminated |
Gastrointestinal Stromal Tumors |
NCT00751036 |
| Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin |
Terminated |
Ovarian Cancer |
NCT00840450 |
| Imatinib Mesylate in Treating Patients With Metastatic Melanoma |
Completed |
Melanoma|Skin Neoplasms |
NCT00027586 |
| Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer |
Completed |
Kidney Cancer |
NCT00331409 |
| Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer |
Completed |
Recurrent Uterine Sarcoma|Uterine Carcinosarcoma |
NCT00075400 |
| Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00193180 |
| Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer |
Terminated |
Prostate Cancer|Prostatic Neoplasms |
NCT00861471 |
| Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. |
Unknown status |
Acute Lymphocytic Leukemia |
NCT00149136 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis |
Completed |
Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis |
NCT00039416 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure |
Completed |
Malignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00026169 |
| Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis |
Completed |
Systemic Sclerosis, Scleroderma |
NCT00613171 |
| Efficacy and Safety of Imatinib in Chordoma |
Completed |
Chordoma |
NCT00150072 |
| Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct |
Completed |
Advanced or Metastatic Cholangiocellular Carcinoma and Bile Duct |
NCT01153750 |
| Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00041340 |
| A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs |
Unknown status |
Gastrointestinal Stromal Tumors (GISTs) |
NCT02712112 |
| Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) |
Completed |
Gastrointestinal Stromal Tumors |
NCT00237172 |
| Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial |
Recruiting |
Chronic Myelogenous Leukemia |
NCT00816114 |
| Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer |
Completed |
Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer |
NCT00041041 |
| Pulmonary Hypertension and Imatinib |
Completed |
PAH |
NCT01092897 |
| Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib |
Completed |
Chronic Myeloid Leukaemia |
NCT01343173 |
| Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma |
Completed |
Mesothelioma |
NCT00402766 |
| Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008) |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00483366 |
| Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors |
Completed |
Unspecified Adult Solid Tumor |
NCT00390156 |
| Effect of Antacids on Gleevec® in Healthy Volunteers |
Completed |
Healthy |
NCT00446316 |
| Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy |
Terminated |
Myeloid Leukemia, Chronic |
NCT02086487 |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma |
Completed |
Adult Synovial Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma |
NCT01281865 |
| TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study |
Unknown status |
Chronic Myeloid Leukemia |
NCT01860456 |
| Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia |
Completed |
Myeloid Leukemia, Chronic |
NCT00478985 |
| Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children |
Completed |
Acute Lymphoblastic Leukemia|Philadelphia Chromosome |
NCT00287105 |
| An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL |
Recruiting |
Lymphoblastic Leukemia, Acute, Adult|Acute Lymphoid Leukemia|Leukemia, Acute Lymphoblastic|Leukemia, Lymphoblastic|Ph1 Chromosome|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
NCT03589326 |
| Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib |
Unknown status |
Chronic Myeloid Leukemia|Imatinib|Complete Molecular Response |
NCT01564836 |
| Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma |
Unknown status |
Chordoma |
NCT01175109 |
| Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA) |
Unknown status |
Chronic Myeloid Leukemia or Ph Positive ALL |
NCT02034656 |
| Efficacy and Safety of Imatinib in Scleroderma |
Completed |
Scleroderma, Localized|Scleroderma, Systemic |
NCT00479934 |
| Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease |
Withdrawn |
Pulmonary Hypertension |
NCT01568645 |
| Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index |
Not yet recruiting |
Gastrointestinal Stromal Tumor |
NCT02576080 |
| A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML |
Completed |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT02896842 |
| Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer |
Completed |
Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer |
NCT00045188 |
| Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor(GIST) |
NCT03440515 |
| Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients |
Terminated |
Gastrointestinal Stromal Tumors|Cancer Brain|Solid Tumors |
NCT00585221 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
Completed |
Acral Lentiginous Malignant Melanoma|Recurrent Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma|Stage IV Melanoma |
NCT00470470 |
| STI571 in Treating Patients With Recurrent Leukemia |
Completed |
Leukemia |
NCT00004932 |
| Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer |
Terminated |
Ovarian Dysgerminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Ovarian Germ Cell Tumor|Stage II Malignant Testicular Germ Cell Tumor|Stage II Ovarian Germ Cell Tumor|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Testicular Seminoma |
NCT00042952 |
| Imatinib Mesylate in Treating Patients With Salivary Gland Cancer |
Completed |
Head and Neck Cancer |
NCT00045669 |
| Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate |
Terminated |
Gastrointestinal Stromal Tumor |
NCT00956072 |
| A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin |
Not yet recruiting |
Tuberculosis |
NCT03891901 |
| Imatinib Mesylate in Treating Patients With Recurrent Meningioma |
Completed |
Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Grade III Meningioma|Adult Meningeal Hemangiopericytoma|Adult Meningioma|Recurrent Adult Brain Tumor |
NCT00045734 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer |
Completed |
Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer |
NCT00036751 |
| Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma |
Terminated |
Brain and Central Nervous System Tumors |
NCT00021229 |
| Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec |
Completed |
Nephrogenic Systemic Fibrosis |
NCT00981942 |
| Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) |
Completed |
Chronic Myelogenous Leukemia in Chronic Phase |
NCT00237120 |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer |
Completed |
Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|KIT Positive|PDGFR Positive|Postmenopausal|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 |
NCT00338728 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases |
Completed |
Life Threatening Diseases |
NCT00154388 |
| Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer |
Completed |
Breast Cancer |
NCT00372476 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
Completed |
Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Gastrointestinal Stromal Tumor|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Meningeal Chronic Myelogenous Leukemia|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Non-Hodgkin Lymphoma|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia |
NCT00025415 |
| The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML |
Completed |
CML, CML-CP,MMR,TKI |
NCT02204644 |
| Safety Study of Gleevec® in Children With Pulmonary Hypertension |
Terminated |
Pulmonary Hypertension |
NCT00583115 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood |
Completed |
Childhood Desmoplastic Small Round Cell Tumor|Childhood Synovial Sarcoma|Gastrointestinal Stromal Tumor|Lung Metastases|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Recurrent Osteosarcoma |
NCT00030667 |
| Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma |
Completed |
Thymic Carcinoma |
NCT00314873 |
| High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) |
Completed |
AML |
NCT00707408 |
| Explore the Synergy of Combination TKI Therapy |
Withdrawn |
Healthy Volunteers |
NCT02129166 |
| Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey |
Completed |
Leukemia, Myeloid, Chronic-Phase (CML-CP) |
NCT01188278 |
| Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) |
Terminated |
Pulmonary Arterial Hypertension |
NCT01392495 |
| Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer |
Completed |
Gastric Cancer |
NCT00601510 |
| Gleevec Study for Patients With Ovarian Cancer |
Completed |
Ovarian Cancer |
NCT00510653 |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
Terminated |
Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Relapsing Chronic Myelogenous Leukemia |
NCT00101088 |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia |
Completed |
Chronic Myelogenous Leukemia |
NCT00333840 |
| Long-term Surival of GIST Patients ≥ 10 Years on Imatinib |
Not yet recruiting |
GIST |
NCT04097093 |
| Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis |
Completed |
Desmoid Tumor |
NCT00287846 |
| Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement |
Unknown status |
Systemic Sclerosis |
NCT00573326 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery |
Terminated |
Gastrointestinal Stromal Tumor |
NCT00091078 |
| Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. |
Terminated |
Chronic Myelogenous Leukemia |
NCT01130688 |
| TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients |
Terminated |
Chronic Myelogenous Leukemia |
NCT00415909 |
| Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C |
Terminated |
Myelogenous Leukemia, Chronic, Chronic Phase |
NCT00038649 |
| Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan |
Completed |
Chronic Myeloid Leukemia, Chronic Phase |
NCT02977312 |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors |
Terminated |
Malignant Peripheral Nerve Sheath Tumors |
NCT00427583 |
| S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer |
Completed |
Breast Cancer |
NCT00087152 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Relapsing Chronic Myelogenous Leukemia |
NCT00049192 |
| to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers |
Completed |
Healthy |
NCT01926548 |
| A Study of Imatinib and Docetaxel in Prostate Cancer |
Completed |
Prostate Cancer |
NCT00251225 |
| Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis |
Completed |
Pulmonary Veno Occlusive Disease |
NCT00891527 |
| Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia |
Completed |
Chronic Myeloid Leukemia |
NCT00947830 |
| The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder |
Available |
Chronic Myeloid Leukemia |
NCT00854841 |
| Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck |
Unknown status |
Cancer of the Head and Neck|Carcinoma, Adenoid Cystic |
NCT00180921 |
| Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) |
Completed |
Chronic Myeloid Leukemia (CML) |
NCT00428909 |
| Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers |
Completed |
Healthy |
NCT00732784 |
| A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer |
Completed |
Recurrent Gastric Cancer|Stage IV Gastric Cancer |
NCT00068380 |
| Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Relapsing Chronic Myelogenous Leukemia |
NCT00054431 |
| Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00248482 |
| To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib. |
Unknown status |
GIST |
NCT03424876 |
| Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases |
Completed |
Metastatic Cancer|Prostate Cancer |
NCT00080678 |
| Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery |
Completed |
Gastrointestinal Stromal Tumor |
NCT00041197 |
| Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) |
Completed |
Chronic Myeloid Leukemia |
NCT00514488 |
| Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) |
Completed |
Chronic Myelogenous Leukemia |
NCT00171899 |
| Effects of Imatinib Mesylate in Polycythemia Vera |
Completed |
Polycythemia Vera |
NCT00430066 |
| Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia |
Completed |
Leukemia |
NCT00268229 |
| Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib |
Completed |
Chronic Phase Chronic Myeloid Leukemia |
NCT01660906 |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients |
Completed |
Chronic Myeloid Leukemia |
NCT01275196 |
| Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia |
NCT00030394 |
| S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer |
Completed |
Recurrent Neuroendocrine Carcinoma of the Skin|Stage II Neuroendocrine Carcinoma of the Skin|Stage III Neuroendocrine Carcinoma of the Skin |
NCT00068783 |
| Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma |
Completed |
Brain and Central Nervous System Tumors |
NCT00401024 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis |
Terminated |
Chronic Myeloproliferative Disorders |
NCT00245128 |
| Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer |
Completed |
Prostate Cancer |
NCT00500110 |
| Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers |
Completed |
Healthy |
NCT00446004 |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00408460 |
| Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC) |
Completed |
Prostate Cancer |
NCT00424385 |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients |
Completed |
3rd Line GIST |
NCT01735968 |
| Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors |
Completed |
Colon Cancer|Colorectal Cancer |
NCT00183833 |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia, Myeloid, Chronic |
NCT00040105 |
| An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia |
Completed |
Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia |
NCT00171223 |
| An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia |
Completed |
Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia |
NCT00171249 |
| Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase |
Withdrawn |
Myeloid Leukemia, Chronic, Chronic-Phase |
NCT00324077 |
| Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years |
Completed |
Chronic Myeloid Leukemia |
NCT00219752 |
| A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia |
Completed |
Myeloid Leukemia, Chronic |
NCT00481247 |
| Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma |
Completed |
Clear Cell Renal Cell Carcinoma |
NCT00193258 |
| Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
Withdrawn |
Choroidal Neovascularization |
NCT00403156 |
| Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes |
Completed |
Leukemia, Myeloid|Myelodysplastic Syndromes |
NCT00451997 |
| Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia |
Completed |
Chronic Myelogenous Leukemia |
NCT00047502 |
| Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) |
Withdrawn |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT02421926 |
| Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor |
NCT00103168 |
| The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia |
Recruiting |
Chronic Myeloid Leukemia|Philadelphia Chromosome Positive CML |
NCT03241199 |
| Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 |
Completed |
Metastatic Cancer|Prostate Cancer |
NCT00084825 |
| Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma |
Completed |
Metastatic Melanoma |
NCT00881049 |
| Imatinib in Dermatofibrosarcoma Protuberans (DFSP) |
Completed |
Dermatofibrosarcoma |
NCT00122473 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Recruiting |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia |
NCT03007147 |
| Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT00281996 |
| Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer |
Completed |
Recurrent Small Cell Lung Cancer |
NCT00052949 |
| Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer |
Terminated |
Breast Cancer |
NCT00323063 |
| Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations |
Terminated |
CML|Philadelphia Chromosome Positive (Ph+)|Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels |
NCT01131325 |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma |
Recruiting |
Effect of Drugs|Quality of Life|Chordoma|Advanced Cancer |
NCT04042597 |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP |
Completed |
Acute Myelogenous Leukemia|Agnogenic Myeloid Metaplasia|Chronic Myelogenous Leukemia |
NCT00088231 |
| New Individualized Therapy Trial for Metastatic Colorectal Cancer |
Completed |
Colorectal Neoplasm|Colorectal Cancer |
NCT00867334 |
| Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor |
Unknown status |
Gastrointestinal Stromal Tumor |
NCT00685828 |
| Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia |
Completed |
Leukemia |
NCT00038610 |
| Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase |
Unknown status |
Chronic Myeloid Leukemia |
NCT00327262 |
| Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor |
Terminated |
Gastrointestinal Stromal Tumor |
NCT00324987 |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) |
Terminated |
Myeloid Leukemia, Chronic|Myeloid Leukemia, Chronic, Accelerated-Phase|Blast Phase|Myeloid Leukemia, Chronic, Chronic-Phase |
NCT00114959 |
| Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor |
NCT00028002 |
| Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia |
Terminated |
Leukemia |
NCT00015847 |
| Treatment of Polycythemia Vera With Gleevec |
Completed |
Polycythemia Vera |
NCT01120821 |
| STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Relapsing Chronic Myelogenous Leukemia |
NCT00015834 |
| Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00222144 |
| Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance |
Completed |
Sarcoma|Gastro-intestinal Stromal Tumors (GIST) |
NCT00367861 |
| Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy |
Completed |
Gastrointestinal Stromal Tumor |
NCT01865565 |
| Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00161213 |
| Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors |
Terminated |
Gastrointestinal Stromal Tumor |
NCT00573404 |
| Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions |
Completed |
Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumor |
NCT02103322 |
| Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00323362 |
| First-line Therapy of Stage IV Colorectal Cancer |
Completed |
Stage IV Colorectal Cancer |
NCT00784446 |
| Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive |
Completed |
Leukemia, Lymphocytic, Acute|Philadelphia Chromosome|Blast Crisis|Leukemia, Myeloid, Chronic |
NCT00763763 |
| Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate |
Completed |
Leukemia |
NCT00093639 |
| LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT02164903 |
| Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) |
Terminated |
Glioblastoma |
NCT00171938 |
| Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia |
Active, not recruiting |
Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
NCT00070499 |
| A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease |
Unknown status |
Graft vs Host Disease |
NCT00760981 |
| RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. |
Withdrawn |
Chronic Myeloid Leukemia |
NCT01188889 |
| Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor |
Terminated |
Gastrointestinal Stromal Tumor |
NCT00009906 |
| Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma |
Unknown status |
Brain and Central Nervous System Tumors |
NCT00904735 |
| Imatinib in Adult Patients With Metastatic Ocular Melanoma |
Terminated |
Melanoma |
NCT00421317 |
| Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia |
Terminated |
Leukemia |
NCT00022490 |
| A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma |
Terminated |
Metastatic Melanoma |
NCT00402662 |
| An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment |
Completed |
Chronic Myelogenous Leukemia |
NCT00980018 |
| Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia |
Completed |
Chronic Myelomonocytic Leukemia|Chronic Myelogenous Leukemia |
NCT00079313 |
| Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 |
Terminated |
Non-small Cell Lung Cancer |
NCT02127372 |
| Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients |
Recruiting |
Leukemia, Chronic Myeloid |
NCT03515018 |
| Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response |
Terminated |
Myeloid Leukemia, Chronic |
NCT00210119 |
| Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor |
Completed |
Adult Anaplastic Oligodendroglioma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm |
NCT00049127 |
| Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia |
Active, not recruiting |
Leukemia |
NCT00301093 |
| Late Chronic Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT01092741 |
| Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers |
Completed |
Healthy |
NCT01653314 |
| Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00084513 |
| Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy |
Completed |
Leukemia |
NCT00509093 |
| Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients |
Terminated |
Chronic Myeloid Leukemia |
NCT00219765 |
| AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year |
Unknown status |
Chronic Myeloid Leukemia |
NCT00146913 |
| Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer |
Completed |
Advanced Pancreatic Cancer |
NCT01048320 |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) |
Completed |
Leukemia, Myeloid, Chronic |
NCT00050531 |
| A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec |
Completed |
Leukemia, Other|Cancer |
NCT00250042 |
| A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma |
Unknown status |
Mesothelioma |
NCT00551252 |
| Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms |
Withdrawn |
Leukemia, Myeloid, Chronic-Phase |
NCT01650467 |
| POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST |
Recruiting |
GIST, Malignant|KIT Exon 13 Mutation|KIT Gene Mutation |
NCT03171389 |
| Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase |
Completed |
Myeloid Leukemia, Chronic, Chronic-Phase |
NCT00510926 |
| Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML |
Completed |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Philadelphia Positive Adult Acute Lymphoblastic Leukemia|Philadelphia Positive Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Relapsing Chronic Myelogenous Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia |
NCT00702403 |
| Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer |
Completed |
Prostate Cancer |
NCT00038194 |
| Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors |
Completed |
Gastric Cancer|Leukemia|Chronic Myelogenous Leukemia |
NCT00580281 |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib |
Terminated |
Chronic Myeloid Leukemia|Gastrointestinal Stromal Cell Tumors|Chromosome Abnormality |
NCT00461929 |
| Phase II Gleevec Idiopathic Hypereosinophilic Syndrome |
Withdrawn |
Eosinophilia|Hypereosinophilic Syndrome |
NCT00230334 |
| De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia |
Unknown status |
Chronic Myeloid Leukaemia |
NCT01804985 |
| Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor |
Completed |
Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00039585 |
| Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+ |
Suspended |
Chronic Myelogenous Leukemia |
NCT01755325 |
| Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate |
Completed |
Cancer |
NCT01046487 |
| Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study. |
Withdrawn |
Metastatic Solid Tumors. |
NCT00159016 |
| Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response |
Completed |
Chronic Phase Chronic Myeloid Leukemia |
NCT01933906 |
| Glivec in Pediatric Chronic Myeloid Leukemia (CML) |
Completed |
Chronic Myeloid Leukemia |
NCT00845221 |
| Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors |
Terminated |
Gastrointestinal Stromal Tumor |
NCT00372567 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers |
Completed |
Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00074308 |
| Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia |
Completed |
Leukemia |
NCT00244829 |
| Imatinib Mesylate in Treating Patients With Gliomas |
Completed |
Brain and Central Nervous System Tumors |
NCT00039364 |
| Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites |
Recruiting |
Plasmodium Falciparum Malaria (Drug Resistant) |
NCT03697668 |
| Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor |
Completed |
Gastrointestinal Stromal Tumors (GIST) |
NCT00633295 |
| Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00253565 |
| Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma |
Completed |
Brain and Central Nervous System Tumors |
NCT00010049 |
| Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor |
Completed |
Sarcoma |
NCT00062205 |
| Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma |
Completed |
Childhood Malignant Fibrous Histiocytoma of Bone|Sarcoma |
NCT00031915 |
| Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia |
Completed |
Chronic Myeloid Leukaemia |
NCT00390897 |
| Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00425646 |
| Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma |
Completed |
Sarcoma |
NCT00085475 |
| Pioglityazone and Imatinib for CML Patients |
Completed |
Leukemia, Myeloid, Chronic-Phase |
NCT02888964 |
| Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00066326 |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase |
Completed |
Chronic Myeloid Leukemia |
NCT00514969 |
| Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC |
Completed |
Small Cell Lung Cancer |
NCT00156286 |
| STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia |
Completed |
Acute Lymphoblastic Leukemia |
NCT00376467 |
| Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT00471328 |
| STI571 ProspectIve RandomIzed Trial: SPIRIT |
Completed |
Chronic Myeloid Leukemia |
NCT00219739 |
| Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer |
Completed |
Leukemia |
NCT00064285 |
| Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study |
Completed |
Idiopathic Pulmonary Fibrosis|Lung Disease|Pulmonary Fibrosis |
NCT00131274 |
| Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study |
Active, not recruiting |
Treatment|Stem Cell Transplantation |
NCT01025505 |
| Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study |
Unknown status |
CML, Chronic Phase |
NCT02949570 |
| An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
Completed |
Leukemia, Myeloid, Chronic |
NCT00538109 |
| Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia |
Completed |
Chronic Myeloid Leukemia|Philadelphia-Positive Myeloid Leukemia |
NCT00103844 |
| BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate |
Unknown status |
Leukemia |
NCT00112775 |
| A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy |
Terminated |
Leukemia |
NCT00362466 |
| Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST) |
Unknown status |
Gastrointestinal Stromal Tumors |
NCT00290485 |
| Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor |
NCT00112632 |
| Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00081133 |
| Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma |
Completed |
Brain and Central Nervous System Tumors |
NCT00354068 |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease |
Recruiting |
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Minimal Residual Disease |
NCT03516279 |
| Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia |
Completed |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT01437202 |
| Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy |
Completed |
Chronic Myeloid Leukemia |
NCT00896129 |
| Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL |
Terminated |
Acute Lymphoblastic Leukemia |
NCT01148134 |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia |
Completed |
Chronic Myeloid Leukemia |
NCT00511303 |
| Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia |
Withdrawn |
Chronic Myeloid Leukemia |
NCT00573378 |
| Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib |
Completed |
Chronic Myeloid Leukemia|Philadelphia-Positive Myeloid Leukemia |
NCT00101660 |
| Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) |
Terminated |
Gastrointestinal Stromal Tumors |
NCT00812240 |
| A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib |
Completed |
Gastrointestinal Stromal Tumors|Gastrointestinal Neoplasms |
NCT00570635 |
| A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients |
Terminated |
Chronic Myeloid Leukemia |
NCT02204722 |
| Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib |
Completed |
Advanced Gastrointestinal Stromal Tumors |
NCT01907607 |
| Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) |
Unknown status |
AML |
NCT00744081 |
| Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) |
Terminated |
Chronic Myeloid Leukemia |
NCT01650805 |
| Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00052494 |
| Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Completed |
Adult Acute Lymphoblastic Leukemia in Remission |
NCT00039377 |
| Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia |
Unknown status |
Leukemia |
NCT00028847 |
| Glivec Phase II Pediatric Study |
Terminated |
Cancer |
NCT00180830 |
| Early Conversion of Dasatinib in CML-CP Patients |
Enrolling by invitation |
Validity and Safety |
NCT04136015 |
| Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00045604 |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib |
Completed |
Gastro Intestinal Stromal Tumor |
NCT01506336 |
| Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib |
Terminated |
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia |
NCT02115386 |
| STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma |
Completed |
Endometrial Cancer|Gastrointestinal Stromal Tumor|Ovarian Cancer|Sarcoma|Small Intestine Cancer |
NCT00006357 |
| Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00053248 |
| Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE |
Recruiting |
Acute Lymphoblastic Leukemia Ph Positive |
NCT01491763 |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis |
Completed |
Leukemia |
NCT00006475 |
| Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy |
Unknown status |
Leukemia, Myeloid, Philadelphia-Positive |
NCT00297570 |
| STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00006052 |
| Treatment Modification Based on Early Assessment of CML Patients |
Unknown status |
CML |
NCT01762969 |
| Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00045422 |
| Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL |
Withdrawn |
Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia |
NCT00349518 |
| Glivec in Ph Positive Lymphoblastic Leukemia |
Completed |
Acute Lymphoblastic Leukemia|Cromosome Philadelphia Positive |
NCT00388895 |
| Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia |
Recruiting |
Chronyc Myeloid Leukemia |
NCT02602314 |
| Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients |
Completed |
Pulmonary Arterial Hypertension |
NCT01392469 |
| Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00618501 |
| Sorafenib for Imatinib/Sunitinib-failed GIST |
Completed |
Gastrointestinal Stromal Tumors |
NCT01091207 |
| Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) |
Completed |
Chronic Myeloid Leukemia |
NCT01394666 |
| Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias |
Unknown status |
Hypereosinophilic Syndrome|Chronic Eosinophilic Leukemia (CEL)|Myeloproliferative Disorders |
NCT00276926 |
| A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib |
Active, not recruiting |
Leukemia |
NCT00777036 |
| A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment |
Recruiting |
Gastrointestinal Stromal Tumors|Germline Mutation|Somatic Mutation|Plasma Concentration |
NCT03092128 |
| Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00258271 |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) |
Completed |
Acute Lymphoblastic Leukemia |
NCT00130195 |
| STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa |
Completed |
Leukemia |
NCT00006053 |
| Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) |
Terminated |
Chronic Myeloid Leukemia |
NCT00511121 |
| Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors |
Completed |
Gastrointestinal Stromal Tumors |
NCT00293124 |
| Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia |
Unknown status |
Leukemia |
NCT01227135 |
| L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors |
Recruiting |
Gastrointestinal Stromal Tumors (GISTs) |
NCT03426722 |
| Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib |
Recruiting |
Chronic Myeloid Leukemia|Chronic Phase|Adults |
NCT02398825 |
| Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT04106024 |
| Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes |
Not yet recruiting |
Patients Diagnosed as Chronic Meyloid Leukemia |
NCT04326933 |
| Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) |
Unknown status |
Philadelphia Positive Acute Lymphoblastic Leukemia|Lymphoid Blastic Phase of Chronic Myeloid Leukemia |
NCT00199186 |
| Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. |
Completed |
Gastrointestinal Stromal Tumors |
NCT01289028 |
| Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer |
Terminated |
Kidney Cancer |
NCT00323791 |
| Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 |
Completed |
Gastrointestinal Stromal Tumors |
NCT01440959 |
| A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia |
Completed |
Myeloid Leukemia, Chronic |
NCT00482703 |
| Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia |
No longer available |
Chronic Myeloid Leukemia |
NCT00302016 |
| Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome |
Recruiting |
Eosinophilic Myeloid Neoplasm|Hypereosinophilic Syndrome |
NCT00044304 |
| Autologous Transplantation for Chronic Myelogenous Leukemia |
Completed |
Chronic Myelogenous Leukemia |
NCT01003054 |
| Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib |
Active, not recruiting |
Gastrointestinal Stromal Tumors |
NCT01694277 |
| Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors |
NCT00793871 |
| Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia |
Recruiting |
Chronic Myeloid Leukaemia |
NCT02001818 |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients |
Completed |
Leukemia|Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia |
NCT00493181 |
| Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy |
Completed |
Leukemia, Myeloid, Chronic |
NCT00264160 |
| Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT00718562 |
| Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant |
No longer available |
Chronic Myelogenous Leukemia |
NCT00413270 |
| Jejunoileal vs Gastric GIST in the Era of Imatinib. |
Completed |
Disease-free Survival|Overall Survival|Recurrence |
NCT03923400 |
| Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00982488 |
| A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT03673501 |
| Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib |
Terminated |
Gastrointestinal Stromal Tumors |
NCT00688766 |
| Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib |
Unknown status |
Chronic Myeloid Leukemia |
NCT01562847 |
| A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib |
Recruiting |
Chronic Myeloid Leukemia |
NCT01215487 |
| Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
Suspended |
Gastro Intestinal Stromal Tumour |
NCT04193553 |
| Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT02607332 |
| Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) |
Completed |
Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia |
NCT01279473 |
| Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT01478373 |
| Tasigna in Glivec-resistant or Intolerant Patients in CML |
Completed |
CML|Nilotinib|Imatinib Resistant|Imatinib Intolerant |
NCT01206088 |
| Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission |
Unknown status |
Chronic Myelogenous Leukemia|Short Stature |
NCT01901666 |
| Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) |
Completed |
Chronic Myelogenous Leukemia |
NCT00042003 |
| Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) |
Completed |
Chronic Myelogenous Leukemia |
NCT00042016 |
| A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia |
Completed |
Chronic Myeloid Leukemia |
NCT00866736 |
| Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec |
Completed |
Chronic Myelogenous Leukemia |
NCT00661180 |
| Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial |
Completed |
Chronic Myelogenous Leukemia |
NCT01368523 |
| Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) |
Completed |
Chronic Myelogenous Leukemia |
NCT00041990 |
| Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT03944304 |
| Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib |
Completed |
Chronic Myelogenous Leukemia - Chronic Phase |
NCT00644878 |
| Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib |
Completed |
Gastrointestinal Stromal Tumors |
NCT01524848 |
| Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
Completed |
Chronic Myeloid Leukemia|Blast Crisis |
NCT00101816 |
| Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease |
Completed |
Chronic Myeloid Leukemia|Minimal Residual Disease |
NCT00267085 |
| Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects |
Active, not recruiting |
Leukemia |
NCT00529763 |
| Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
Completed |
Gastrointestinal Stromal Tumor |
NCT01110668 |
| Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00458848 |
| Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha |
Terminated |
Chronic Myeloid Leukemia |
NCT01073436 |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib |
Active, not recruiting |
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive |
NCT01746836 |
| A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib. |
Unknown status |
Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib |
NCT01227746 |
| Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan |
Completed |
Chronic Myelogenous Leukemia |
NCT00337454 |
| PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib |
Completed |
Sarcoma |
NCT00117299 |
| A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate |
Completed |
Leukemia, Myeloid, Chronic|Leukemia, Lymphocytic, Acute, L2 |
NCT00298987 |
| Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer |
Completed |
Prostate Cancer |
NCT00427999 |
| Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00055874 |
| Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate |
Completed |
Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Meningeal Chronic Myelogenous Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Relapsing Chronic Myelogenous Leukemia|Unspecified Childhood Solid Tumor, Protocol Specific |
NCT00316953 |
| AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ |
Terminated |
Leukemia, Myeloid, Chronic |
NCT00058747 |
| Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate |
Active, not recruiting |
Gastrointestinal Stromal Tumor |
NCT00265798 |
| Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy |
Terminated |
Chronic Phase CML |
NCT01490775 |
| BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate |
Completed |
Leukemia |
NCT00064233 |
| Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00193349 |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation |
Completed |
Chronic Myelogenous Leukemia (CML) |
NCT01243489 |
| Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer |
Terminated |
Advanced Colorectal Cancer |
NCT01271166 |
| Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
Completed |
Chronic Myeloid Leukemia |
NCT00786812 |
| Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R) |
Terminated |
Leukemia |
NCT00415857 |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers |
Completed |
Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)|Hypereosinophilic Syndrome|Systemic Mastocytosis |
NCT00109707 |
| STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00006343 |
| Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) |
Active, not recruiting |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT01774630 |
| Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility |
Completed |
Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumors |
NCT01114087 |
| Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation |
Recruiting |
Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST |
NCT03381053 |
| Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
Approved for marketing |
Chronic Myeloid Leukemia |
NCT00905593 |
| Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) |
Terminated |
Gastrointestinal Stromal Tumor (GIST) |
NCT01391611 |
| STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia |
Completed |
Leukemia |
NCT00015860 |
| Role of Gene Variation in Effectiveness of Gleevec Treatment |
Completed |
Cancer|Breast Cancer |
NCT00342056 |
| Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
Completed |
Chronic Myelogenous Leukemia |
NCT00081926 |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) |
Completed |
Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia |
NCT01077544 |
| Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response |
Recruiting |
Leukemia, Chronic Myeloid |
NCT02326311 |
| Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors |
Completed |
Advanced Gastrointestinal Stromal Tumor |
NCT00254267 |
| Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00769327 |
| A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase |
Completed |
Chronic Myeloid Leukemia |
NCT01126892 |
| Frontline Asciminib Combination in Chronic Phase CML |
Recruiting |
Chronic Myeloid Leukemia |
NCT03906292 |
| Registration of Children With CML and Treatment With Imatinib |
Unknown status |
Myeloid Leukemia, Chronic |
NCT00445822 |
| Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response |
Completed |
Philadelphia Chromosome Positive|Chronic Myelogenous Leukemia in Chronic Phase |
NCT01043874 |
| A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL |
Completed |
Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) |
NCT00384228 |
| PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy |
Unknown status |
Leukemia |
NCT00335868 |
| Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia |
Not yet recruiting |
Chronic Myeloid Leukemia, Chronic Phase|Withdrawal;Drug |
NCT04147533 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate |
Completed |
Leukemia |
NCT00100997 |
| A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation |
Completed |
CML |
NCT01744665 |
| Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer |
Recruiting |
Stomach Neoplasms |
NCT03170180 |
| Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia |
Completed |
L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia |
NCT00049569 |
| A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies |
Completed |
Hematologic Malignancy |
NCT02352558 |
| Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia |
Recruiting |
Chronic Myeloid Leukemia |
NCT04043676 |
| Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia |
Completed |
Chronic Myeloid Leukemia|Acute Lymphocytic Leukemia |
NCT00352677 |
| A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients |
Unknown status |
Gastrointestinal Stromal Tumor |
NCT01389583 |
| Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase |
Unknown status |
Chronic Myeloid Leukemia |
NCT01802450 |
| A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL |
Recruiting |
Chronic Myelogenous Leukemia|Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia |
NCT02081378 |
| Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia |
Unknown status |
Chronic Myeloid Leukemia Patients |
NCT03214718 |
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. |
Active, not recruiting |
Leukemia|Leukemia,Pediatric|Leukemia, Myleiod|Leukemia, Mylegenous, Chronic|Leukemia, Mylegenous, Accelerated|BCR-ABL Positive|Myeloproliferative Disorder|Bone Marrow Disease|Hematologic Diseases|Neoplastic Processes|Imatinib|Dasatinib|Enzyme Inhibitor|Protein Kinase Inhibitor |
NCT01844765 |
| Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients |
Recruiting |
CML, Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia, Chronic Phase |
NCT03885830 |
| Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib |
Completed |
Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blastic Phase|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase of Disease|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Disease |
NCT00036738 |
| Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia |
Completed |
Chronic Myelogenous Leukemia |
NCT00101647 |
| Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML |
Completed |
Myeloid Leukemia, Chronic, Chronic-Phase |
NCT00123474 |
| Safety Assessment of a Multipeptide-gene Vaccine in CML |
Completed |
Leukemia, Myeloid, Chronic |
NCT00455221 |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI |
Completed |
Leukemia|Leukemia, Myeloid|Leukemia, Myelogenous, Chronic, BCR-ABL Positive|Philadelphia Chromosome|Hematologic Diseases |
NCT01602952 |
| To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission |
Active, not recruiting |
Chronic Myeloid Leukemia|Treatment Free Remission |
NCT03062436 |
| A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia |
Active, not recruiting |
Chronic Phase Chronic Myeloid Leukemia |
NCT02627677 |
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Completed |
Chronic Myeloid Leukemia|Leukemia, Lymphoblastic, Acute, Philadelphia-positive |
NCT00101595 |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate |
Terminated |
Accelerated Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia|Relapsing Chronic Myelogenous Leukemia |
NCT01426334 |
| Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia |
Completed |
Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia |
NCT00022737 |
| Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor |
Active, not recruiting |
Gastrointestinal Stromal Tumor |
NCT01068769 |
| Epacadostat and Pembrolizumab in Patients With GIST |
Active, not recruiting |
Gastrointestinal Stromal Tumors |
NCT03291054 |
| Nilotinib Plus Pegylated Interferon-α2b in CML |
Terminated |
Chronic Myeloid Leukemia |
NCT01866553 |
| A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs |
Recruiting |
Leukemia, Myeloid, Chronic Phase |
NCT03459534 |
| Compassionate Use Ponatinib |
No longer available |
Philadelphia Chromosome Positive (Ph+) Leukemias|Chronic Myeloid Leukemia |
NCT01549548 |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) |
Completed |
GIST |
NCT01323400 |
| A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) |
Completed |
Gastrointestinal Stromal Tumor |
NCT00075218 |
| Rollover Study of BMS-354825 in Patients With CML and Ph+ALL |
Completed |
Chronic Myelogenous Leukemia|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
NCT01030718 |
| Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs |
Completed |
Gastrointestinal Stromal Tumors (GISTs) |
NCT02889328 |
| Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) |
Terminated |
Gastrointestinal Stromal Tumors |
NCT00782834 |
| The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). |
Completed |
Gastrointestinal Stromal Tumors|Soft Tissue Sarcomas |
NCT00385203 |
| Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST |
Completed |
Sarcoma|Malignant Gastrointestinal Stromal Tumor |
NCT00359333 |
| Ph II CABOGIST in GIST |
Active, not recruiting |
Metastatic Gastrointestinal Stromal Tumor |
NCT02216578 |
| Korean Early Access Program |
Approved for marketing |
Leukemia |
NCT00454753 |
| Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML |
Completed |
Myeloid Leukemia, Chronic, Accelerated Phase|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
NCT00123487 |
| Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia |
Active, not recruiting |
Leukemia |
NCT01319981 |
| Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK |
Completed |
Gastrointestinal Stromal Tumors |
NCT00976612 |
| Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML |
Terminated |
Leukemia |
NCT00416884 |
| Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) |
Completed |
Gastrointestinal Stromal Tumors |
NCT01271712 |
| Sarcopenia in Patients With Gastrointestinal Stromal Tumours |
Completed |
Gastrointestinal Stromal Tumours |
NCT02877368 |
| Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC |
Not yet recruiting |
Lung Diseases|Neoplasms|Respiratory Tract Diseases|Thoracic Neoplasms|Non-Small-Cell Lung |
NCT03389256 |
| Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults |
Completed |
Leukemia, Lymphocytic |
NCT00327678 |
| Telemonitoring Study - for Chronic Myeloid Leukemia (CML) |
Terminated |
Chronic Myeloid Leukemia |
NCT01490983 |
| Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumor|Metastatic Cancer |
NCT00769782 |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease |
Recruiting |
Hematological Neoplasms |
NCT03844360 |
| (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST |
Active, not recruiting |
GIST |
NCT03465722 |
| Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias |
Completed |
Chronic Myelogenous Leukemia |
NCT00811070 |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors |
Terminated |
Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission|Minimal Residual Disease|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia |
NCT01751425 |
| Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) |
Terminated |
Acute Lymphoblastic Leukemia |
NCT01312818 |
| Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT01244750 |
| Treatment-free Remission Accomplished With Dasatinib in Patients With CML |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT02268370 |
| Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. |
Terminated |
Philidelphia Positive Chronic Myeloid Leukaemia |
NCT02108951 |
| Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI |
Completed |
Leukemia |
NCT00363649 |
| A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study |
Unknown status |
Gastrointestinal Cancers |
NCT02013089 |
| Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients |
Unknown status |
Chronic Myelogenous Leukaemia |
NCT03205267 |
| Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients |
Terminated |
Chronic Myeloid Leukemia |
NCT01169753 |
| Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy |
No longer available |
Gastrointestinal Stromal Tumors |
NCT01646593 |
| Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) |
No longer available |
Gastrointestinal Stromal Tumors |
NCT01689376 |
| Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants |
Withdrawn |
HIV Infections |
NCT04041674 |
| The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients |
Completed |
Healthy |
NCT01743300 |
| A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) |
Completed |
Gastrointestinal Stromal Tumors |
NCT00457743 |
| Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) |
Completed |
Gastrointestinal Cancer |
NCT00089960 |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00466726 |
| A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) |
Completed |
Gastrointestinal Stromal Tumor |
NCT01039519 |
| An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) |
Completed |
GIST |
NCT00618319 |
| A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 |
Approved for marketing |
Gastrointestinal Neoplasm |
NCT00094029 |
| Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib |
Completed |
GIST |
NCT01459757 |
| PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors |
Active, not recruiting |
Gastrointestinal Stromal Tumors |
NCT02401815 |
| SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) |
Withdrawn |
Gastrointestinal Stromal Tumors |
NCT02342600 |
| The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) |
Active, not recruiting |
Leukemia, Myeloid, Chronic |
NCT02269267 |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
Completed |
Chronic Myeloid Leukemia |
NCT00815321 |
| Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination |
No longer available |
Gastrointestinal Stromal Tumor |
NCT01613053 |
| PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study |
Recruiting |
Asthma |
NCT04129931 |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment |
Recruiting |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma |
NCT02881086 |
| Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) |
Terminated |
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML)|Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL) |
NCT00860535 |
| A Treatment Study Protocol for Participants 1-45 Years With Acute Lymphoblastic Leukaemia |
Not yet recruiting |
Leukemia, Acute Lymphoblastic |
NCT04307576 |
| Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia |
Completed |
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myeloid Leukemia |
NCT00469014 |
| Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients |
Terminated |
Metastatic Renal Cell Carcinoma |
NCT01073644 |
| Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) |
Terminated |
Chronic Myelogenous Leukemia |
NCT01397734 |
| Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Terminated |
Leukemia |
NCT01005914 |
| The Study to YD312 Tablet in Patients With Diabetic Macular Edema |
Active, not recruiting |
Diabetic Macular Edema(DME) |
NCT03635814 |
| Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy |
Recruiting |
Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML |
NCT02638428 |
| the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) |
Not yet recruiting |
Non-small Cell Lung Cancer |
NCT03264794 |
| Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
Recruiting |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma |
NCT03023046 |
| Treatment of Older Adults With Acute Lymphoblastic Leukemia |
Completed |
Acute Lymphoblastic Leukemia |
NCT00973752 |
| A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia |
Recruiting |
Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia |
NCT03878524 |
| Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
Withdrawn |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma |
NCT02538926 |
| Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML |
Unknown status |
Chronic Myeloid Leukemia in Myeloid Blast Crisis|Untreated Adult Acute Myeloid Leukemia |
NCT01690065 |
| Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT00481052 |
| Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia |
Completed |
Chronic Myeloid Leukemia |
NCT01805843 |
| Study of Nilotinib in Metastatic Melanoma With KIT Aberrations |
Completed |
Metastatic Melanoma With KIT Aberration |
NCT01099514 |
| Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia |
Completed |
Leukemia, Lymphoblastic, Acute |
NCT02888990 |
| Withdrawal or Reduction TKIs in CML-CP |
Recruiting |
MMR on 12 Month |
NCT04143087 |
| A Study for Tyrosine Kinase Inhibitors Discontinuation |
Recruiting |
Leukemia |
NCT02897245 |
| Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years |
Recruiting |
Acute Lymphoblastic Leukemia Ph Positive |
NCT01376427 |
| Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States |
Recruiting |
Chronic Phase Chronic Myeloid Leukemia |
NCT03045120 |
| Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL |
Recruiting |
Lymphoblastic Leukemia, Acute |
NCT02888977 |
| Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) |
Completed |
Philadelphia Positive Acute Lymphoblastic Leukemia |
NCT01724879 |
| Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia |
Completed |
Leukemia, Myeloid, Chronic-Phase |
NCT01725204 |
| Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease |
Completed |
Leukemia |
NCT00819143 |
| Phase II Pazopanib Study in Advanced Dermatofibrosarcomas |
Terminated |
Dermatofibrosarcomas of DARIER FERRAND(DFSP) |
NCT01059656 |
| A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT04258956 |
| Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach |
Unknown status |
Hematologic Diseases|Chronic Myeloid Leukemia |
NCT03540654 |
| Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib |
Completed |
Myeloid Leukemia, Chronic, Chronic-Phase |
NCT02348957 |
| Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment |
Unknown status |
Cancer |
NCT01370980 |
| Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST) |
Recruiting |
Gastro Intestinal Stromal Tumor |
NCT03963544 |
| Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor |
Completed |
Gastrointestinal Stromal Tumors |
NCT00137449 |
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Terminated |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoblastic Leukemia |
NCT00905398 |
| Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor |
Not yet recruiting |
Chronic Phase Chronic Myelogenous Leukemia |
NCT03907670 |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation |
Completed |
Chronic Myeloid Leukemia |
NCT00375219 |
| BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia |
Completed |
Leukemia, Myeloid, Chronic-phase|Leukemia, Lymphoblastic, Acute, Philadelphia-positive |
NCT00103701 |
| Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) |
Recruiting |
Leukemia, Myeloid, Chronic-Phase |
NCT02767063 |
| Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST |
Active, not recruiting |
Gastrointestinal Stromal Tumor |
NCT02164240 |
| Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer |
Unknown status |
Non Small Cell Lung Cancer |
NCT01019798 |
| G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission |
Completed |
Leukemia |
NCT00233961 |
| Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) |
Active, not recruiting |
Chronic Myeloid Leukemia |
NCT01698905 |
| Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies |
Active, not recruiting |
Gastrointestinal Stromal Tumors |
NCT03353753 |
| Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia |
Terminated |
Chronic Myeloid Leukemia |
NCT00895297 |
| Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. |
Recruiting |
Chronic Myeloid Leukemia|Tyrosine Kinase Inhibitor|Withdrawal Syndrome |
NCT03996096 |
| A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor |
Unknown status |
Gastrointestinal Stromal Tumor |
NCT02336724 |
| A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer |
Unknown status |
Reccurent/Metastatic Solid Tumor Disease |
NCT01771458 |
| Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase |
Completed |
Chronic Phase of Chronic Myeloid Leukemia |
NCT01872442 |
| Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) |
Recruiting |
Gastrointestinal Stromal Tumors|Sdh|GIST|Cancer |
NCT03556384 |
| Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia |
Recruiting |
Leukemia, Myelogenous, Chronic Phase |
NCT03131986 |
| Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma |
Completed |
Mucosal Lentiginous Melanoma|Acral Melanoma|Melanoma |
NCT00788775 |
| SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes |
Recruiting |
Liposarcoma|Osteogenic Sarcoma|Ewing/Ewing-like Sarcoma|Rhabdomyosarcoma |
NCT02048371 |
| Use of Tamoxifen in Systemic Mastocytosis |
Recruiting |
Systemic Mastocytosis |
NCT01334996 |
| Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia |
Completed |
Acute Lymphoblastic Leukemia |
NCT00795756 |
| First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL |
Completed |
Acute Lymphoblastic Leukemia |
NCT01004497 |
| Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) |
Completed |
Chronic Myeloid Leukemia |
NCT00257647 |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. |
Active, not recruiting |
Leukemia, Myeloid, Ph1-Positive |
NCT01743989 |
| Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD |
Completed |
Chronic Graft Versus Host Disease |
NCT01810718 |
| Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) |
Completed |
Chronic Myeloid Leukemia |
NCT00827138 |
| Allogeneic SCT for CML, TKI Failure After TKI Failure |
Unknown status |
Chronic Myeloid Leukemia |
NCT02172365 |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) |
Terminated |
Leukemia |
NCT01392170 |
| Nilotinib Pre and Post Allogeneic Stem Cell Transplantation |
Completed |
Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Stem Cell Transplantation |
NCT00750659 |
| Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. |
Active, not recruiting |
Philadelphia Positive|BCR-ABL Positive|Acute Lymphoblastic Leukemia |
NCT01641107 |
| Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia |
Not yet recruiting |
Chronic Myeloid Leukemia |
NCT02883036 |
| Effect of 2nd Gen TKI in CML |
Completed |
Myeloid Leukemia, Chronic |
NCT02222272 |
| A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma |
Completed |
Anaplastic Astrocytoma|Glioblastoma |
NCT00606008 |
| A Phase I/Expansion Study of Dasatinib |
Terminated |
Refractory Solid Tumors|Pancreatic Adenocarcinoma |
NCT00598091 |
| Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs |
Completed |
Cancer |
NCT01098500 |
| Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia |
Completed |
Leukemia |
NCT00427791 |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer |
Completed |
Paraganglioma|Gastrointestinal Stromal Tumors|Carcinoma, Renal Cell|Renal Neoplasms|Pheochromocytoma |
NCT03165721 |
| OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) |
Completed |
Chronic Myelogenous Leukemia, BCR/ABL Positive |
NCT01916785 |
| Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality |
Recruiting |
Chronic Myeloid Leukemia (CML) |
NCT03746054 |
| GIST: Assessment of Tumor Mutations and TKI Plasma Exposure |
Recruiting |
Gastro-intestinal Stromal Tumor |
NCT02331914 |
| A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT02847377 |
| Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia |
Completed |
Leukemia |
NCT00511069 |
| Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations |
Active, not recruiting |
EGFR Gene Mutation|Nonsmall Cell Lung Cancer |
NCT02954523 |
| Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma |
Recruiting |
Recurrent Glioblastoma |
NCT03632135 |
| To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib |
Completed |
Cancer |
NCT01548170 |
| Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease |
Completed |
BRAF V600E Mutation |
NCT02281760 |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib |
Completed |
Solid Tumor|Metastatic Colorectal Cancer |
NCT00920868 |
| Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
NCT01429610 |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy |
Recruiting |
CML|GIST |
NCT03880617 |
| A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma |
Completed |
Lung Diseases, Interstitial |
NCT01553981 |
| TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia |
Unknown status |
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia|Stem Cell Transplantation|Minimal Residual Disease |
NCT01883219 |
| Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants |
Recruiting |
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia|Tyrosine Kinase Inhibitor|Minimal Residual Disease|Allogeneic Hematopoietic Stem Cell Transplantation |
NCT03624530 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients |
Completed |
Chronic Myeloid Leukemia |
NCT01254188 |
| Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST |
Unknown status |
Gastrointestinal Stromal Tumor |
NCT02353052 |
| Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia |
Unknown status |
Chronic Phase Chronic Myeloid Leukemia|Accelerated Phase Chronic Myeloid Leukemia|Blastic Phase Chronic Myeloid Leukemia|Philadelphia Positive Acute Lymphoblastic Leukemia|Resistant to Tyrosine Kinase Inhibitor Therapy |
NCT01914484 |
| Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia |
Unknown status |
Leukemia, Lymphoblastic, Acute |
NCT03331211 |
| A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase |
Recruiting |
Chronic Myeloid Leukemia, Chronic Phase |
NCT04126681 |
| Personalized Therapy of Precursor Lymphoid Neoplasms |
Unknown status |
Precursor Lymphoid Neoplasms |
NCT01665001 |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors |
Recruiting |
Chronic Phase Chronic Myeloid Leukemia|Chronic Myeloid Leukemia, Chronic Phase |
NCT03610971 |
| Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) |
Completed |
Leukemia |
NCT01460498 |
| Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus |
Completed |
Chronic Graft-versus-host Disease |
NCT01862965 |
| An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia |
Terminated |
Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia |
NCT00346632 |
| Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia |
Terminated |
Leukemia|Lymphoma |
NCT00882206 |
| Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia |
Active, not recruiting |
Leukemia |
NCT00306202 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Completed |
Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms |
NCT02788201 |
| Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib |
Completed |
Chronic Myeloid Leukemia (CML) |
NCT02733445 |
| Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial |
Withdrawn |
Gastrointestinal Neoplasm |
NCT00640692 |
| Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia |
Recruiting |
Leukemia, Myeloid, Chronic|Myeloid Leukemia|Chronic Myeloid Leukemia |
NCT04260022 |
| Natural History Study of Patients With Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00429910 |
| Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene |
Completed |
Gastrointestinal Stromal Tumors |
NCT00444795 |
| Treatment of Patients With RAD001 With Progressive Sarcoma |
Completed |
Progressive Sarcoma |
NCT00767819 |
| Post Transplant Donor Lymphocyte Infusion |
Terminated |
Leukemia, Myeloid, Chronic|Lymphomas|Multiple Myeloma|Myelodysplastic Syndrome|Leukemia, Lymphocytic, Acute|Leukemia, Lymphocytic, Chronic|AML |
NCT00167180 |
| Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Recruiting |
Leukemia|Mucositis|Oral Complications |
NCT01085617 |
| Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Unknown status |
Leukemia |
NCT01005758 |
| Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia |
Completed |
Leukemia |
NCT00110058 |
| Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia |
Completed |
Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia |
NCT00061945 |
| Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission |
Completed |
Leukemia |
NCT00002514 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia |
Not yet recruiting |
Chronic Myeloid Leukemia, Chronic Phase |
NCT04006847 |
| (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors |
Active, not recruiting |
Gastrointestinal Stromal Tumors (GIST)|Other Relapsed or Refractory Solid Tumors |
NCT02508532 |
| Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia |
Completed |
Lymphoblastic Leukemia, Acute |
NCT00137111 |
| A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) |
Active, not recruiting |
Graft-versus-host Disease (GVHD) |
NCT03112603 |
| Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study |
Unknown status |
Acute Lymphoblastic Leukemia (ALL) |
NCT02894645 |
| Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma |
Not yet recruiting |
Melanoma |
NCT02645149 |
| A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults |
Recruiting |
Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia |
NCT02611492 |
| ALL Adult Consortium Trial: Adult ALL Trial |
Active, not recruiting |
Acute Lymphoblastic Leukemia |
NCT00476190 |
| Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting |
Completed |
Gastrointestinal Stromal Tumors |
NCT00877045 |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation |
Completed |
Leukemia|Lymphoma|Allogeneic Haematopoietic Stem Cell Transplantation|Acute Lymphoblastic Leukemia |
NCT00990249 |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy |
Completed |
Metastatic Cancer |
NCT02142036 |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias |
Completed |
Chronic Myeloid Leukemia |
NCT00261846 |
| COMPERA / COMPERA-KIDS |
Recruiting |
Pulmonary Arterial Hypertension (PAH)|Pulmonary Hypertension (PH) |
NCT01347216 |
| A Study for Older Adults With Acute Lymphoblastic Leukaemia |
Active, not recruiting |
Acute Lymphoblastic Leukaemia |
NCT01616238 |
| Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma |
Completed |
Liposarcoma|Leiomyosarcoma|Fibrosarcoma|Malignant Fibrous Histiocytoma |
NCT00400569 |
| High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
Acute Leukemia of Ambiguous Lineage|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia |
NCT02551718 |
| Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study |
Completed |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
NCT02389972 |
| DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) |
Recruiting |
Gastrointestinal Stromal Tumors |
NCT04276415 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias |
Terminated |
Myelodysplastic Syndrome|Acute Myeloid Leukemia|Myeloproliferative Disorders|Acute Lymphocytic Leukemia|Acute Promyelocytic Leukemia|Acute Leukemia|Chronic Myelogenous Leukemia|Myelofibrosis|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia |
NCT00852709 |
| A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands |
Completed |
Chronic Myeloid Leukaemia |
NCT02546375 |
| A Study for Patients With Acute Leukemia |
Terminated |
Acute Leukemia |
NCT01214655 |
